3/5
08:52 am
tcrx
TScan Therapeutics (TCRX) had its price target raised by Wedbush from $4.00 to $5.00. They now have an "outperform" rating on the stock.
Medium
Report
TScan Therapeutics (TCRX) had its price target raised by Wedbush from $4.00 to $5.00. They now have an "outperform" rating on the stock.
3/4
07:25 am
tcrx
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/4
07:00 am
tcrx
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/26
07:09 am
tcrx
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 [Yahoo! Finance]
Neutral
Report
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 [Yahoo! Finance]
2/26
07:00 am
tcrx
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
Low
Report
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
2/25
07:18 am
tcrx
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Medium
Report
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/25
07:00 am
tcrx
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
1/24
05:10 am
tcrx
TScan Therapeutics (NASDAQ:TCRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
TScan Therapeutics (NASDAQ:TCRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/6
05:30 pm
tcrx
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Medium
Report
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition